PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
18.43%
Some net income increase while AGEN is negative at -6.57%. John Neff would see a short-term edge over the struggling competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-43.55%
Negative yoy SBC while AGEN is 6.51%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
69.28%
Slight usage while AGEN is negative at -189.16%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Lower AP growth vs. AGEN's 313.11%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
-92.45%
Both reduce yoy usage, with AGEN at -476.48%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
109.32%
Lower 'other non-cash' growth vs. AGEN's 460.96%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
22.94%
Some CFO growth while AGEN is negative at -8.32%. John Neff would note a short-term liquidity lead over the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.52%
We cut debt repayment yoy while AGEN is 58.23%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
1850.82%
We slightly raise equity while AGEN is negative at -69.43%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.